Compugen Ltd.
A clinical-stage company developing cancer immunotherapies using an AI platform.
CGEN | TA
Overview
Corporate Details
- ISIN(s):
- IL0010852080
- LEI:
- Country:
- Israel
- Address:
- 26 Harokmim St., Bldg D, 5885849 Holon
- Website:
- https://www.cgen.com/
Description
Compugen Ltd. is a clinical-stage therapeutic discovery and development company specializing in cancer immunotherapy. A pioneer in its field, the company leverages a proprietary, broadly applicable, and predictive AI-powered computational discovery platform to identify novel drug targets. Its primary focus is on developing innovative, first-in-class therapeutics designed to modulate the tumor microenvironment and enhance anti-tumor immune responses. Compugen's mission is to advance its pipeline of drug candidates to address patient populations unresponsive to current immunotherapy treatments.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2023-05-15 15:59 |
Form 6-K- First Quarter 2023 Results
|
English | 84.5 KB | ||
| 2023-05-15 15:59 |
Form 6-K- First Quarter 2023 Results
|
English | 36.2 KB | ||
| 2023-05-11 15:59 |
Compugen to Host DNAM-1 Axis Virtual Investor Event with KOL Drew Pardoll on Tu…
|
English | 88.2 KB | ||
| 2023-05-11 15:59 |
Compugen to Host DNAM-1 Axis Virtual Investor Event with KOL Drew Pardoll on Tu…
|
English | 36.0 KB | ||
| 2023-05-09 15:59 |
Compugen to Present at the JMP Securities Life Sciences Conference
|
English | 81.4 KB | ||
| 2023-05-09 15:59 |
Compugen to Present at the JMP Securities Life Sciences Conference
|
English | 36.0 KB | ||
| 2023-05-03 15:59 |
Nasdaq granted the Company a second period of 180 calendar days, or until Octob…
|
English | 62.8 KB | ||
| 2023-05-03 15:59 |
Nasdaq granted the Company a second period of 180 calendar days, or until Octob…
|
English | 36.1 KB | ||
| 2023-05-01 15:59 |
to Release First Quarter 2023 Results and conference call on
Monday, May 15, 20…
|
English | 80.8 KB | ||
| 2023-05-01 15:59 |
to Release First Quarter 2023 Results and conference call on
Monday, May 15, 20…
|
English | 36.0 KB | ||
| 2023-04-27 15:59 |
Compugen to Present New Clinical Data Showing Preliminary AntiTumor Activity o…
|
English | 84.7 KB | ||
| 2023-04-27 15:59 |
Compugen to Present New Clinical Data Showing Preliminary AntiTumor Activity o…
|
English | 36.1 KB | ||
| 2023-04-26 15:59 |
Compugen to Present Data on its Lead Pre-Clinical Asset COM503 in an Oral Prese…
|
English | 97.4 KB | ||
| 2023-04-26 15:59 |
Compugen to Present Data on its Lead Pre-Clinical Asset COM503 in an Oral Prese…
|
English | 36.0 KB | ||
| 2023-04-15 01:04 |
FORM F-3-mendment No. 1-TO PROSPECTUS Dated April 14, 2023
|
English | 325.7 KB |
Automate Your Workflow. Get a real-time feed of all Compugen Ltd. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Compugen Ltd.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Compugen Ltd. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
